Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2

A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401.

(2017) W. K. Kelly et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting castration-induced tumour hypoxia enhances the acute effects of castration therapy in a rat prostate cancer model

(2010) Anna Johansson et al.   BJU INTERNATIONAL

ERβ Impedes Prostate Cancer EMT by Destabilizing HIF-1α and Inhibiting VEGF-Mediated Snail Nuclear Localization: Implications for Gleason Grading

(2010) Paul Mak et al.   CANCER CELL

Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth

(2010) H. Hashizume et al.   CANCER RESEARCH

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma

(2010) Iris Helfrich et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

(2010) J. L. Brown et al.   MOLECULAR CANCER THERAPEUTICS

ADAMTS1, a putative anti-angiogenic factor, is decreased in human prostate cancer

(2009) Heléne Gustavsson et al.   BJU INTERNATIONAL

Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer models

(2008) Tajana Tešan et al.   BJU INTERNATIONAL

Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts

(2008) K Welén et al.   PROSTATE CANCER AND PROSTATIC DISEASES